147 related articles for article (PubMed ID: 31274231)
1. Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients.
Brown TA; Byrd K; Vreeland TJ; Clifton GT; Jackson DO; Hale DF; Herbert GS; Myers JW; Greene JM; Berry JS; Martin J; Elkas JC; Conrads TP; Darcy KM; Hamilton CA; Maxwel GL; Peoples GE
Cancer Med; 2019 Aug; 8(10):4678-4687. PubMed ID: 31274231
[TBL] [Abstract][Full Text] [Related]
2. Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients.
Jackson DO; Byrd K; Vreeland TJ; Hale DF; Herbert GS; Greene JM; Schneble EJ; Berry JS; Trappey AF; Clifton GT; Hardin MO; Martin J; Elkas JC; Conrads TP; Darcy KM; Hamilton CA; Maxwell GL; Peoples GE
Oncotarget; 2017 Feb; 8(9):15912-15923. PubMed ID: 27852036
[TBL] [Abstract][Full Text] [Related]
3. Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39': An analysis of safety and immune response.
Vreeland TJ; Litton JK; Qiao N; Philips AV; Alatrash G; Hale DF; Jackson DO; Peace KM; Greene JM; Berry JS; Clifton GT; Peoples GE; Mittendorf EA
Clin Immunol; 2018 Jul; 192():6-13. PubMed ID: 29574039
[TBL] [Abstract][Full Text] [Related]
4. Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients.
Mittendorf EA; Clifton GT; Holmes JP; Schneble E; van Echo D; Ponniah S; Peoples GE
Ann Oncol; 2014 Sep; 25(9):1735-1742. PubMed ID: 24907636
[TBL] [Abstract][Full Text] [Related]
5. Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence.
Brown TA; Mittendorf EA; Hale DF; Myers JW; Peace KM; Jackson DO; Greene JM; Vreeland TJ; Clifton GT; Ardavanis A; Litton JK; Shumway NM; Symanowski J; Murray JL; Ponniah S; Anastasopoulou EA; Pistamaltzian NF; Baxevanis CN; Perez SA; Papamichail M; Peoples GE
Breast Cancer Res Treat; 2020 Jun; 181(2):391-401. PubMed ID: 32323103
[TBL] [Abstract][Full Text] [Related]
6. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Mittendorf EA; Clifton GT; Holmes JP; Clive KS; Patil R; Benavides LC; Gates JD; Sears AK; Stojadinovic A; Ponniah S; Peoples GE
Cancer; 2012 May; 118(10):2594-602. PubMed ID: 21989902
[TBL] [Abstract][Full Text] [Related]
7. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence.
Mittendorf EA; Ardavanis A; Litton JK; Shumway NM; Hale DF; Murray JL; Perez SA; Ponniah S; Baxevanis CN; Papamichail M; Peoples GE
Oncotarget; 2016 Oct; 7(40):66192-66201. PubMed ID: 27589688
[TBL] [Abstract][Full Text] [Related]
8. Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Amin A; Benavides LC; Holmes JP; Gates JD; Carmichael MG; Hueman MT; Mittendorf EA; Storrer CE; Jama YH; Craig D; Stojadinovic A; Ponniah S; Peoples GE
Cancer Immunol Immunother; 2008 Dec; 57(12):1817-25. PubMed ID: 18392824
[TBL] [Abstract][Full Text] [Related]
9. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients.
Rahma OE; Ashtar E; Czystowska M; Szajnik ME; Wieckowski E; Bernstein S; Herrin VE; Shams MA; Steinberg SM; Merino M; Gooding W; Visus C; Deleo AB; Wolf JK; Bell JG; Berzofsky JA; Whiteside TL; Khleif SN
Cancer Immunol Immunother; 2012 Mar; 61(3):373-84. PubMed ID: 21927947
[TBL] [Abstract][Full Text] [Related]
10. Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Holmes JP; Gates JD; Benavides LC; Hueman MT; Carmichael MG; Patil R; Craig D; Mittendorf EA; Stojadinovic A; Ponniah S; Peoples GE
Cancer; 2008 Oct; 113(7):1666-75. PubMed ID: 18726994
[TBL] [Abstract][Full Text] [Related]
11. Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697).
Lawson DH; Lee S; Zhao F; Tarhini AA; Margolin KA; Ernstoff MS; Atkins MB; Cohen GI; Whiteside TL; Butterfield LH; Kirkwood JM
J Clin Oncol; 2015 Dec; 33(34):4066-76. PubMed ID: 26351350
[TBL] [Abstract][Full Text] [Related]
12. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence.
Mittendorf EA; Ardavanis A; Symanowski J; Murray JL; Shumway NM; Litton JK; Hale DF; Perez SA; Anastasopoulou EA; Pistamaltzian NF; Ponniah S; Baxevanis CN; von Hofe E; Papamichail M; Peoples GE
Ann Oncol; 2016 Jul; 27(7):1241-8. PubMed ID: 27029708
[TBL] [Abstract][Full Text] [Related]
13. Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697).
Butterfield LH; Zhao F; Lee S; Tarhini AA; Margolin KA; White RL; Atkins MB; Cohen GI; Whiteside TL; Kirkwood JM; Lawson DH
Clin Cancer Res; 2017 Sep; 23(17):5034-5043. PubMed ID: 28536308
[No Abstract] [Full Text] [Related]
14. Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04.
Carmichael MG; Benavides LC; Holmes JP; Gates JD; Mittendorf EA; Ponniah S; Peoples GE
Cancer; 2010 Jan; 116(2):292-301. PubMed ID: 19924797
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of Wilms' Tumor 1 (WT1) peptide vaccine with GM-CSF or CpG in patients with solid malignancy.
Ohno S; Okuyama R; Aruga A; Sugiyama H; Yamamoto M
Anticancer Res; 2012 Jun; 32(6):2263-9. PubMed ID: 22641661
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.
Peoples GE; Gurney JM; Hueman MT; Woll MM; Ryan GB; Storrer CE; Fisher C; Shriver CD; Ioannides CG; Ponniah S
J Clin Oncol; 2005 Oct; 23(30):7536-45. PubMed ID: 16157940
[TBL] [Abstract][Full Text] [Related]
17. Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers.
Peoples GE; Anderson BW; Lee TV; Murray JL; Kudelka AP; Wharton JT; Ioannides CG
Clin Cancer Res; 1999 Dec; 5(12):4214-23. PubMed ID: 10632363
[TBL] [Abstract][Full Text] [Related]
18. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
[TBL] [Abstract][Full Text] [Related]
19. Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ.
O'Shea AE; Clifton GT; Qiao N; Heckman-Stoddard BM; Wojtowicz M; Dimond E; Bedrosian I; Weber D; Garber JE; Husband A; Pastorello R; Lee JJ; Hernandez M; Liu DD; Vornik LA; Brown PH; Alatrash G; Peoples GE; Mittendorf EA
Cancer Prev Res (Phila); 2023 Jun; 16(6):333-341. PubMed ID: 37259799
[TBL] [Abstract][Full Text] [Related]
20. Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients.
Gates JD; Carmichael MG; Benavides LC; Holmes JP; Hueman MT; Woll MM; Ioannides CG; Robson CH; McLeod DG; Ponniah S; Peoples GE
J Am Coll Surg; 2009 Feb; 208(2):193-201. PubMed ID: 19228530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
